Extended 7-Day Wear and 1-Unit Dosing Clearances, and Two ADA Posters Signal a New Standard for Mealtime Insulin Management CeQur®, the company dedicated to simplifying mealtime insulin delivery for people living with diabetes, today announced two recent FDA clearances for CeQur Simplicity™: extended wear of up to seven days and a new 1-unit (1U) device. […]
Recent Posts
- June, 2026CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA
- June, 2025CeQur® Marks 10 Million Mealtime Injections Replaced and Highlights Commercial Expansion
- January, 2025CeQur Closes a $120M Equity Financing to Drive Commercial Growth
- June, 2024CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management
- June, 2021CeQur Appoints Rick Doubleday and Dr. Meret Gaugler to Board of Directors